Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Paclitaxel in Paclitaxel-Resistant Advanced Gastric Cancer
NCT02697838Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Disease Control Rate at 6 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02697838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697838.